Scott Myers, ’94
Scott Myers served as president and CEO of Cascadian Therapeutics since 2016 until the company was recently acquired. Prior to that, he was CEO of Aerocrine AB, a life sciences company, from 2011 until Circassia Pharmaceuticals plc acquired it in 2015. From 2007 to 2011, Scott oversaw commercial operations and medical affairs for 32 countries in Europe in his role as VP of UCB SA, a biopharmaceutical company. From 2005-07, he served as the CCO for DOV Pharmaceutical, a development-stage pharmaceutical company; and from 2000-05, Scott held several senior positions at Johnson & Johnson, including SVP and general manager.
Mr. Myers has been a member of the board of directors of Orexo AB, a pharmaceutical company, and is currently an industry advisor for EQT, an investment fund.
Scott received his BA in biology from Northwestern University and his MBA from the University of Chicago Booth School of Business.